One-year risk of @entity146 hospitalization and associated treatment costs in XXXX treated with atypical antipsychotics: a retrospective claims database analysis.

@entity1 @entity162 @entity146 @entity1280 @entity1037 @entity1770 @entity1089 @entity1090
BACKGROUND: This study compared 1-year risk of @entity146 hospitalization and treatment costs in commercially insured @entity1 with @entity162 , treated with @entity1770 , @entity1280 , @entity1037 , @entity1089 or @entity1090 . METHODS: This was a retrospective propensity score-matched cohort study using the Ingenix Lab/Rx integrated insurance claims dataset. @entity1 with @entity162 and 180 days of pre-index enrollment without antipsychotic exposure who received atypical antipsychotic agents were followed for up to 12 months following the initial antipsychotic prescription. The primary analysis used Cox proportional hazards regression to evaluate time-dependent risk of hospitalization, adjusting for age, sex and pre-index hospitalization. Generalized gamma regression compared post-index costs between treatment groups. RESULTS: Compared to @entity1770 , @entity1280 , @entity1037 and @entity1089 had higher risks for hospitalization (hazard ratio 1.96, 1.55 and 1.56, respectively; p < 0.05); @entity1090 had a numerically higher but not statistically different risk (hazard ratio 1.37; p = 0.10). Mental health treatment costs were significantly lower for @entity1770 compared with @entity1280 (p = 0.004) and @entity1089 (p = 0.007), but not compared to @entity1037 (p = 0.29) or @entity1090 (p = 0.80). Total healthcare costs were significantly lower for @entity1770 compared to @entity1089 (p = 0.040) but not other comparators. CONCLUSIONS: In commercially insured adults with @entity162 followed for 1 year after initiation of atypical antipsychotics, treatment with @entity1770 was associated with a lower risk of @entity146 hospitalization than @entity1280 , @entity1089 , @entity1037 and @entity1090 , although this did not reach significance with the latter. @entity1770 was also associated with significantly lower total healthcare costs than @entity1089 , but not the other comparators.
